IOL Chemicals and Pharmaceuticals Limited — Q4 FY25 earnings call

Call held 20 May 2025

Management summary

IOL Chemicals and Pharmaceuticals reported a resilient Q4 FY25 with revenue growing 4.7% YoY to INR528 crores and EBITDA increasing 17% to INR67 crores, driven by improved traction in Ibuprofen and enhanced efficiencies in chemical operations. Despite industry-wide pricing pressures in the pharmaceutical sector and lower-than-expected Paracetamol demand, the company successfully commissioned a fully backward integrated Paracetamol unit and acquired land for future expansion. The net debt to equity ratio remained low at 0.09, providing ample headroom for future growth.

Highlights

  • Revenue from operations for Q4 FY25 grew to INR528 crores, a 4.7% year-on-year growth compared to INR504 crores in Q4 FY24.

  • EBITDA for Q4 FY25 increased by 17% to INR67 crores, up from INR58 crores in Q4 FY24, translating to an EBITDA margin of 12.7% (an improvement of 141 basis points YoY).

  • Profit after tax for Q4 FY25 grew by 12% year-on-year to INR31.6 crores compared to INR28 crores in Q4 FY24, with a PAT margin of 5.9% (an increase of 43 basis points).

  • Cash PAT for Q4 FY25 stood at INR56.4 crores, an increase of about 15% compared to INR49.2 crores in Q4 FY24.

  • Successfully commissioned a fully backward integrated Paracetamol unit at a cost of INR155 crore, funded entirely through internal accruals, increasing Paracetamol capacity to 10,800 MTPA.

Concerns

  • The pharmaceutical sector experienced persistent pricing pressure driven by global oversupply and aggressive pricing from new entrants, impacting margins across the industry.

  • Total PAT for the full year FY25 was impacted by higher depreciation charges largely stemming from recent capital investments.

  • Demand for Paracetamol was not up to the mark during FY25, despite capacity expansion.

  • API prices, including Ibuprofen, have seen a decline of around 25% over the last 5 years, although management believes they have bottomed out.

Key financials

2 periods

Q4 FY25

  • Revenue
    ₹528 Cr
    YoY +4.7%
  • EBITDA
    ₹67 Cr
    YoY +17%
  • EBITDA Margin
    12.7%
  • PAT
    ₹31.6 Cr
    YoY +12%
  • PAT Margin
    5.9%
  • Cash PAT
    ₹56.4 Cr
    YoY +15%

FY25

  • Revenue
    ₹2,079 Cr
  • EBITDA
    ₹225 Cr
  • EBITDA Margin
    11%
  • PAT
    ₹101 Cr
  • PAT Margin
    4.8%
  • Cash PAT
    ₹185 Cr

What they filed

Q1 FY27: revenue up 37.0%, net profit up 88.2% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue526 523 528 552 568 +8%580 +11%619 +17%756 +37%
EBITDA42 47 63 62 57 +36%57 +21%93 +48%104 +68%
Net profit19 21 32 34 30 +58%21 +0%53 +66%64 +88%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • API
    65% Ibuprofen Revenue Share (Q4 FY25)35% Non-Ibu Revenue Share (Q4 FY25)
  • Chemicals
    6% EBITDA Margin (Q4 FY25)3% EBITDA Margin (FY24)

Capital allocation

high confidence
  • Capex ₹150 Cr INR155 crore investment funded entirely through internal accruals
    • Fully backward integrated Paracetamol unit ₹155 Cr
    • Growth capex, infra, automation, and developments ₹200 Cr
    This INR155 crore investment funded entirely through internal accruals has enhanced our Paracetamol capacity to 10,800 MTPA. This is a major step in strengthening our non-Ibu portfolio, which now contributes about 34% to the API revenues, up from 18% just 5 years ago.
  • Debt Debt disclosed
    Our net debt to equity ratio stood at 0.09 on account of working capital borrowing at the end of financial year '25 reflecting a minimal leverage and strong internal accruals.

Guidance & targets

Revenue

  • Export Revenue Share Revenue · medium term · Medium confidence 40%
    Currently, our export revenues stand at around 27% and we aim to scale this to about 40% over the medium term.

    — Abhay Raj Singh

  • Peak Revenue from Existing Capacity Revenue · Medium confidence INR2,700 crores to INR2,800 crores
    So, considering the current price, the peak revenue from the existing capacity is something around INR2,700 crores to INR2,800 crores.

    — Abhay Raj Singh

  • Revenue Growth Revenue · FY26 · Medium confidence 10% to 15%
    We are expecting 10% to 15% growth in revenue from all the products. So, it is a mix of both volume and prices.

    — Kushal Kumar Rana

  • Export Sale (API) Revenue · next 2 years · Medium confidence 40% to 45%
    And we hope that in the year or maybe by the next 2 years, we will be able to achieve the export realization or export sale of around 40% to 45%.

    — Abhay Raj Singh

Capacity

  • Paracetamol Capacity Capacity · High confidence 10,800 MTPA
    Paracetamol capacity to 10,800 MTPA.

    — Abhay Raj Singh

Margin

  • Chemical Segment EBITDA Margin Margin · current year (FY26) · Medium confidence more than 6%

    From 3% today

    In the fourth quarter of '25, we have achieved 6% EBITDA margin from chemicals as compared to '24, 3%. So we are going forward to 10%. So hopefully in the current year, we will achieve more than 6%.

    — Kushal Kumar Rana

  • Chemical Segment EBITDA Margin Margin · Low confidence 10%
    Approximately 10% is the better margin for chemical sector.

    — Kushal Kumar Rana

  • EBITDA Margin Margin · current year (FY26) · Medium confidence more than 15%

    From 11% today

    In the last quarter i.e., in the fourth quarter of '25, we have EBITDA margin of approximately 13%. So, we are expecting more than 15% in the current year.

    — Kushal Kumar Rana

What to watch in Q1 FY26

FY26 Revenue Growth

Next quarter (Q1 FY26 results)
Current Q4 FY25 Revenue up 4.7% YoY; FY25 Revenue INR2,079 crores
Target 10-15% growth for FY26

Why it matters

Key indicator of overall business performance and market traction, reflecting the impact of new capacities and market strategies.

We are expecting 10% to 15% growth in revenue from all the products. So, it is a mix of both volume and prices.

Risks & concerns

  • Pharmaceutical Sector Pricing Pressure

    medium

    Global oversupply and aggressive pricing from new entrants, especially in India, impacting margins.

    Management acknowledged

  • API Price Decline

    medium

    Prices for non-Ibu products and Ibuprofen declined by around 25% over the last 5 years, though believed to have bottomed out.

    Management acknowledged

  • Higher Depreciation Charges

    low

    Impacting total PAT due to recent capital investments.

    Management acknowledged

  • Paracetamol Demand

    low

    Demand for Paracetamol was not up to the mark during FY25.

    Management acknowledged

  • Competition from New Players in Ibuprofen

    low

    Management acknowledges it's an open market but relies on strategy, operational efficiency, quality, and marketing to compete.

    Analyst downplayed

Q&A highlights

6 direct
Levetiracetam Molecule Performance and Market Outlook Direct
I think Levetiracetam, yes, the quantity will increase because we have already done some capacity enhancements for Levetiracetam also and we are approaching new customers as well and we have filed U.S. DMF for this product also. So we are expecting good volumes in near future.

Provides insight into growth drivers for a specific non-Ibu API, including capacity expansion, new customer acquisition, and regulatory filings for key markets.

Asked by Vivek Patel

Ibuprofen Export to China after CDE Approval Direct
I think definitely this is a new market for us since we have got the approval from the regulatory authority of China and there are good volumes there for Ibuprofen and other derivatives also. So I think we have started touching our customers there in China. So we can make a forecast over a period of time that how much material we can sell into that market.

Highlights a new market opportunity for Ibuprofen and potential for future revenue contribution, though specific volume/value is yet to be determined.

Asked by Aryan Jain

Chemical Sector Price Realizations and Margin Improvement Partial
Primarily we are working on internal efficiencies and how to reduce the cost of production. No doubt the prices are totally linked with the raw material prices, but still, we develop various mechanisms how we can get low cost of production keeping in view the volatility in the raw material prices.

Addresses concerns about low margins in the chemical sector and management's strategy to improve profitability through internal efficiencies, acknowledging raw material price linkage.

Asked by Aryan Jain

API Margin Differential between Ibuprofen and Other APIs Direct
Surabhi, this is Abhay. Actually, we are unable to comment how the others are doing. But as you know that for the Ibuprofen, we are the backward integrated facility and we command the backward chain also and we are considered as one of the best cost-efficient company for the Ibuprofen.

Explains the company's competitive advantage in Ibuprofen due to backward integration and cost efficiency, suggesting resilience despite industry pressures.

Asked by Surabhi

Pharma Segment Revenue and EBIT Drop in FY25 Direct
One of the reasons is that our quantity production and sale is increasing from the last quarter. That's why the improvement in the API segment in the quarter 4. But as we have previously explained that the prices we think are at bottom out for all the API since last 2, 3 quarters. We hope that this price will not be sustainable and maybe time to come it may be start improving.

Clarifies the reasons for the decline in pharma segment performance in FY25, attributing Q4 improvement to increased volumes and a belief that API prices have bottomed out.

Asked by Sahil Vohra

Strategy to Achieve 40-45% Export Revenue Target Direct
So basically, Sahil, for most of our non-Ibuprofen portfolio, we are having the regulatory approvals from European market, Brazilian market and we also have for some from the Russian and the Korean and China as well. So, these are majorly the European country and we are targeting. And we hope that in the year or maybe by the next 2 years, we will be able to achieve the export realization or export sale of around 40% to 45%.

Outlines the specific markets and regulatory strategies for increasing export revenue, indicating a clear path for international expansion.

Asked by Sahil Vohra

US FDA Inspection for Regulatory Approvals Partial
I think U.S. FDA approval is clearly proceeded as per the regulatory or authority requirements, which means the company has nothing to do with the inspection. As and when they will plan for the inspection, they will come for the inspection. I think as far as the company part is concerned, recently we have got approval for our Fenofibrate product in U.S. where we got some 2, 3 questions for the DMF and then later on after submission of the response, our customer got the approval for that. So I think it is very difficult to comment when U.S. FDA inspection will take place. But yes, as a company, we are ready for the inspection.

Addresses the status of US FDA approvals and inspections, indicating readiness but uncertainty on timing, while confirming a recent approval for Fenofibrate.

Asked by Raj Patel

Paracetamol Capacity Clarification Direct
No. We also clarified this thing in the last presentation and the press releases when we given it last time also. So you need to understand the background. We were having before this the 1 plant, which was having the overall capacity of 3,600 MTPA. Now we come up with the new plant, this plant is having the capacity of 10,800 MTPA. Presently both the plants are running. But our plan is that the old plant, 3,600 MTPA capacity, all the production will shift to the new plant. So off late we will have 10,800 tons capacity and the plant, which is existing plant 3,600 tons, will be converted for some other products. This is on the basis of the current scenario.

Clarifies the company's Paracetamol capacity, explaining the transition from an older plant to a new, larger facility and future plans for the older plant.

Asked by Hemant Kanungo

3 min read 6 chapters

Detailed narrative

Q4 FY25 and Full Year Performance Overview

IOL Chemicals and Pharmaceuticals reported a resilient Q4 FY25 with revenue from operations growing 4.7% year-on-year to INR528 crores. EBITDA for the quarter increased by 17% to INR67 crores, resulting in an EBITDA margin of 12.7%, a 141 basis points improvement. Profit after tax grew 12% to INR31.6 crores, with a PAT margin of 5.9%. For the full year FY25, revenue stood at INR2,079 crores, with an EBITDA of INR225 crores (11% margin) and PAT of INR101 crores (4.8% margin). Cash PAT for Q4 FY25 was INR56.4 crores, underscoring strong cash generation.

Strategic Capacity Expansion and Diversification

The company successfully commissioned a fully backward integrated Paracetamol unit with an investment of INR155 crores, funded entirely through internal accruals. This expansion has increased Paracetamol capacity to 10,800 MTPA, significantly strengthening the non-Ibu portfolio, which now contributes 34% to API revenues, up from 18% five years ago. Additionally, IOL Chemicals acquired 101 acres of land along the Chandigarh-Bathinda Highway for greenfield expansion, with necessary industrial, environmental, and NHI clearances currently underway and progressing into FY26.

API Segment Dynamics and Market Outlook

In the API segment, Ibuprofen showed improved traction in Q4 FY25 despite ongoing price challenges. Other therapeutic categories like antidiabetics, analgesics, and cardiovascular APIs (e.g., Metformin, Fenofibrate, Pantoprazole, Levetiracetam, Clopidogrel) saw stable demand. Clopidogrel capacity was expanded by 33%. While API prices, including Ibuprofen, have declined by approximately 25% over the last five years, management believes prices have bottomed out and may see improvement going forward, with positive volume traction in Ibuprofen and some non-Ibu segments.

Chemical Business Performance and Margin Improvement

The chemical operations delivered stable financial performance, supported by enhanced efficiencies and better cost control. The EBITDA margin for the chemical segment improved to 6% in Q4 FY25, up from 3% in FY24. Management aims to achieve more than 6% in the current year (FY26) and eventually target 10% for the chemical sector. The merchant sale in chemicals is primarily for Ethyl Acetate, where prices have stabilized, and demand is showing increasing traction.

Focus on Export Market Expansion

IOL Chemicals is strategically focused on scaling its export revenues from the current 27% to about 40% over the medium term, and specifically 40-45% for API exports within the next two years. This will be achieved by leveraging regulatory approvals (DMFs and CEPs) in key markets such as Europe, Brazil, Russia, Korea, and China for its non-Ibuprofen portfolio. The company has already received CDE approval for Ibuprofen export to China and is actively engaging with customers in this new market.

Financial Strength and Future Growth Outlook

The company maintains a strong financial foundation with a net debt to equity ratio of 0.09 at the end of FY25, reflecting minimal leverage and robust internal accruals. This provides ample headroom for funding future growth and strategic initiatives. For FY26, management expects a revenue growth of 10-15% and an EBITDA margin exceeding 15%, driven by a mix of volume and price improvements, and continued focus on operational discipline and portfolio diversification.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls